New study tracks biosimilar drug zedora in early breast cancer patients
NCT ID NCT03892655
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study follows 170 women with early-stage HER2-positive breast cancer who received the biosimilar drug Zedora after surgery. Researchers want to see how well it prevents the cancer from coming back and how safe it is in everyday medical practice. The goal is to gather real-world data on effectiveness and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Andrea Juliana Pereira de Santana Gomes
Natal, Rio Grande do Norte, 59075740, Brazil
-
Charles Alain Cordova Pinto
Lages, Santa Catarina, Brazil
-
Cláudio Rocha
Teresina, Piauí, 64049-200, Brazil
-
Cristina de Deus Anjos Tavares Sampaio
Campo Grande, Mato Grosso, Brazil
-
Daniel Fontes Santos de Teive e Argolo
Salvador, Estado de Bahia, 41810570, Brazil
-
Daniel Grabarz
Mogi das Cruzes, São Paulo, 08730500, Brazil
-
Kaique Almeida
São Paulo, São Paulo, Brazil
-
Karina Costa Maia Vianna
Curitiba, Paraná, Brazil
-
Luis Eduardo Rosa Zucca
Três Lagoas, Mato Grosso do Sul, Brazil
-
Mariana Scaranti
São Paulo, São Paulo, Brazil
-
Mateus Bongers Alessandretti
Porto Alegre, Rio Grande do Sul, Brazil
-
Micheline Campos Rezende
Muriaé, Minas Gerais, Brazil
-
Monique Celeste Tavares
São Paulo, São Paulo, 01509-900, Brazil
-
Márcia Cristina Colares Régis de Araújo
Fortaleza, Ceará, 60135285, Brazil
-
Rafaela Kirchner Piccoli
Ijuí, Rio Grande do Sul, Brazil
-
Raphael Luzorio Fernandes
Cachoeiro de Itapemirim, Espírito Santo, Brazil
-
Ruffo de Freitas Junior
Goiânia, Goiás, Brazil
-
Sabina Bandeira Aleixo
Cachoeiro de Itapemirim, Espírito Santo, Brazil
-
Sâmio Pimentel Ferreira
Belém, Pará, 66035265, Brazil
-
Sérgio Lunardon Padilha
Curitiba, Paraná, Brazil
-
Tomas Reinert
Caxias do Sul, Rio Grande do Sul, Brazil
-
William Hiromi Fuzita
Manaus, Amazonas, 69057205, Brazil
Conditions
Explore the condition pages connected to this study.